-
1 week ago | 
newtothestreet.com | Bryan Johnson
Investors looking for new opportunities in the entertainment sector—discover how the MUSQ ETF is revolutionizing global music investments. In this episode of New to The Street (Ep. 655), host Jane King interviews David Schulhof, founder and CEO of MUSQ, the first-ever music-focused exchange-traded fund (ETF) traded on the NYSE. Learn how MUSQ provides exposure to 30+ public music companies worldwide—including Spotify, Live Nation, Tencent Music, Yamaha, and more.
-
1 week ago | 
newtothestreet.com | Bryan Johnson
Investors, discover how gold is making a comeback as real money. In this episode of New to The Street, Jason Cozens, CEO of Glint, dives into Florida’s groundbreaking legislation recognizing gold and silver as legal tender—and how Glint is already enabling everyday gold transactions via its app and Mastercard.
-
2 weeks ago | 
newtothestreet.com | Bryan Johnson
๐ Entrepreneurs and business owners โ learn how to revolutionize your employee benefits strategy!In this episode of New to The Street (Ep. 655) airing on Bloomberg, Fox, and YouTube, industry leaders from HILB Group and Health In Tech (HIT) reveal a groundbreaking partnership thatโs transforming health care for small and mid-sized businesses.
-
2 weeks ago | 
newtothestreet.com | Bryan Johnson
For investors and healthcare innovators, this episode of New to The Street dives deep into NRx Pharmaceuticals’ game-changing approach to mental health treatment. CEO Dr. Jonathan Javitt reveals how their reformulated, preservative-free intravenous ketamine is set to revolutionize the $750M+ ketamine market while offering hope to veterans and others battling suicidal depression and PTSD.
-
2 weeks ago | 
newtothestreet.com | Bryan Johnson
Investors, discover how the live music explosion is reshaping markets. David Schulhof, Founder & CEO of the MUSQ ETF, breaks down how his fund taps into the multi-billion-dollar global music industry—from streaming giants like Spotify and Apple Music to live events, ticketing, and next-gen venues like The Sphere. Schulhof shares why he believes music is an undervalued asset class, how tour economics are changing post-COVID, and why MUSQ is outperforming major indices in 2024.
-
3 weeks ago | 
newtothestreet.com | Bryan Johnson
For blockchain investors and tech innovators:In this episode of New to The Street – Exploring the Block (Ep. 670), Pedro Vidal, Chief Relationship Officer at FlowKey, dives into the project’s groundbreaking approach to decentralized finance, gaming, and tokenization. FlowKey stands out with its community-led governance, blockchain-native MMORPG Valhalla, and innovative DeFi tools like the FlokiFi token locker—the only ERC-1155 compatible solution of its kind.
-
3 weeks ago | 
newtothestreet.com | Bryan Johnson
Investors, tech innovators, and crypto enthusiasts – don’t miss New to The Street Ep. 659, airing on Bloomberg TV and YouTube. In this episode:🛠️ FlowKey/Floki’s Pedro Vidal unveils cutting-edge blockchain tools, from DeFi token lockers to a massive MMO-RPG launch. 🚚 Arrive AI CEO Dan O’Toole details their autonomous delivery tech and final crowdfunding push before going public (Nasdaq: ARAI).
-
3 weeks ago | 
newtothestreet.com | Bryan Johnson
Investors and tech innovators â discover how Commercialville.TV is redefining search with a patented, video-first platform that skips outdated link-clicking and delivers immersive, direct-to-consumer results. In this New to The Street Episode 655, Paul Lawrence, spokesperson for Commercialville.TV, explains how the platform empowers small businesses with affordable ad options, ZIP-code targeting, and seamless user experience.
-
3 weeks ago | 
newtothestreet.com | Bryan Johnson
Investors and healthcare innovators—don’t miss this exclusive update from Biovie Inc., a clinical-stage biopharma company developing revolutionary treatments for neurological and neurodegenerative disorders. In New to The Street Ep. 655, host Jane King interviews CEO Khang Do and Advisory Board member Kush Saxena about Biovie’s promising drug candidate, Benzisterum, now in clinical trials for long COVID and Parkinson’s disease.
-
3 weeks ago | 
newtothestreet.com | Bryan Johnson
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettvFollow New to the Street on Twitter: https://twitter.com/NewToTheStreetFollow New to the Street on Facebook: https://www.facebook.com/newtothestreet/About New to the Street: https://newtothestreet.com/
